Cutaneous T-Cell Lymphoma Therapy: Your 2026 Stage-by-Stage Guide

Introduction: Finding Your Place in the CTCL Treatment Landscape

People researching cutaneous T-cell lymphoma (CTCL) treatment often find information that is hard to use. Most resources are organized by drug class, mechanism of action, or clinical trial phase. A patient, however, does not start with a drug class. Instead, a patient starts with a stage, a set of symptoms, and a treatment history, and needs to know which options apply.

This guide is organized around three decision pathways that reflect where patients actually are:

1. Newly diagnosed, skin-limited mycosis fungoides (MF)
2. Blood-involved disease, including Sézary syndrome (SS) and erythrodermic MF
3. Relapsed or refractory CTCL

Two features set this guide apart. First, it includes clear “when to escalate” signposts that help patients and caregivers recognize when it is time to move to the next level of care. Second, it explains in plain terms why CAR-T cell therapy, which has transformed B-cell lymphoma treatment, is unusually difficult to build for CTCL.

This 2026 edition reflects the latest developments, including the approval of denileukin diftitox-cxdl (Lymphir), lacutamab’s Breakthrough Therapy designation, the confirmatory TELLOMAK-3 trial, and the FLASH2 timeline for HyBryte.

One point deserves emphasis before the details: early-stage CTCL is often a chronic, manageable condition, not an immediate crisis. Many patients live with it for decades. Understanding the pathway can turn uncertainty into an informed plan.

Understanding Cutaneous T-Cell Lymphoma: A Quick Primer

CTCL is a group of non-Hodgkin lymphomas that arise from T-cells that normally travel to and live in the skin. The two forms patients most often encounter are mycosis fungoides and Sézary syndrome.

How common is CTCL?

• Overall CTCL incidence in the United States is approximately 8.55 per million people, and it has been rising over time.
• Roughly 18,000 people in the US are estimated to be living with CTCL.
• The median age at diagnosis is around 50 years, and the disease is more common in older adults and people with compromised immune systems.
• CTCL is about twice as common in men as in women.
• People of Sub-Saharan African descent in the US are about twice as likely to develop CTCL as those of European descent.

MF versus SS

Feature	Mycosis Fungoides (MF)	Sézary Syndrome (SS)
Share of CTCL cases	About 50% to 70%	About 1% to 3%
Primary location	Skin (patches, plaques, sometimes tumors)	Skin, blood, and lymph nodes
Typical presentation	Often slow-growing and skin-confined	Widespread redness of the skin (erythroderma), circulating malignant cells, enlarged lymph nodes

Why staging matters more than diagnosis

A CTCL diagnosis alone does not determine treatment. Stage does. Staging considers how much skin is involved, whether lesions are patches, plaques, or tumors, and whether disease has reached the lymph nodes, blood, or internal organs. A person with a few patches on the trunk and a person with high blood involvement both have CTCL, but their treatment plans look very different. The rest of this guide follows that logic.

Pathway 1: Newly Diagnosed, Skin-Limited Mycosis Fungoides

This is the most common starting point, and it carries the best long-term outlook. Patients with stage IA MF have a median survival of 35.5 years and a disease-specific survival of 90% at 20 years. For many, the goal is long-term control and comfort rather than an aggressive cure attempt.

Why skin-directed therapy comes first

National Comprehensive Cancer Network (NCCN) guidance recommends skin-directed therapy as the preferred first-line approach for limited-stage disease. About 70% of primary cutaneous lymphomas remain confined to the skin, often for years to decades. Treating the skin directly avoids exposing the whole body to systemic drugs while the disease is still localized.

Common skin-directed options include:

• Topical corticosteroids: Often the first step for limited patches.
• Topical mechlorethamine: A topical chemotherapy gel applied to lesions.
• Topical retinoids: Vitamin A-derived agents that influence how abnormal cells grow and mature.
• Phototherapy: Controlled ultraviolet light treatment (narrowband UVB or PUVA), usually given in a clinic several times per week.
• Local radiation: Effective for individual thick plaques or tumors.
• Total skin electron beam therapy (TSEBT): For generalized skin involvement, NCCN recommends TSEBT at 12 to 36 Gy, often followed by maintenance systemic therapy such as interferon or bexarotene.

An emerging option to watch: HyBryte

Currently, no front-line systemic therapy is FDA-approved for early-stage CTCL; all approved systemic drugs require prior treatment failure. This gap is why HyBryte (synthetic hypericin photodynamic therapy) is being developed as a potential first-line option for early-stage disease.

HyBryte’s regulatory path has not been simple. The FDA issued a Refusal to File letter for its original New Drug Application, finding the submission incomplete for review, and later required a second confirmatory Phase 3 trial, known as FLASH2. Interim data from an investigator-initiated extension study showed that 75% of evaluated early-stage patients achieved “Treatment Success” (at least 50% improvement in lesion severity), a response investigators described as notably faster than the six to twelve months most CTCL treatments typically require. FLASH2 top-line results are expected in the second half of 2026, so patients should ask their care team about the latest announcements.

Signpost: When to Escalate from Topicals to Systemic Therapy

Moving beyond skin-directed therapy is a normal part of CTCL management for some patients. Escalation is not a sign of failure or a poor prognosis. It simply means the current tool is no longer the best fit.

Concrete escalation triggers

• No meaningful response after an adequate trial of topical or light-based therapy
• Progression in extent, such as lesions spreading to a larger body surface area
• Progression in thickness, such as patches becoming plaques or plaques becoming tumors
• New lymph node or blood involvement
• Reclassification to stage IIB or higher

NCCN’s threshold

NCCN guidance reserves systemic therapy for stage IIB or higher disease or for confirmed failure of topical treatment.

Tracking milestones objectively

Patients can work with their dermatologist to track measurable markers over time:

• Lesion count and location
• Body surface area (BSA) involved
• Lesion type (patch, plaque, tumor)
• Biopsy changes, including features such as large-cell transformation
• Blood test results, if blood involvement is being monitored

Clinical photographs taken at consistent intervals can also make changes easier to see. Objective tracking helps both patient and physician recognize the right moment to escalate rather than relying on memory or impression.

Pathway 2: Blood-Involved Disease: Sézary Syndrome and Erythrodermic MF

Blood involvement changes the treatment approach fundamentally. Sézary syndrome is a leukemic variant of CTCL, meaning malignant cells circulate in the bloodstream. Skin creams and light treatments cannot reach those cells, so therapy must address the blood compartment. Unlike Pathway 1, systemic or blood-targeted therapy is appropriate from the outset.

Extracorporeal photopheresis (ECP)

ECP is an FDA-approved immunotherapy recommended specifically for patients with Sézary syndrome and erythrodermic stage III MF. The process works as follows:

1. Blood is drawn from the patient.
2. White blood cells are separated out.
3. Those cells are treated with a photosensitizing drug and exposed to UVA light.
4. The treated cells are returned to the patient’s body.

The procedure is thought to stimulate an immune response against the malignant T-cells. Overall response rates to ECP range from 54% to 74%, with complete response rates of 14% to 33.3%. Because ECP requires specialized equipment and trained staff, it is typically offered at specific treatment centers, which can affect access.

Mogamulizumab (Poteligeo)

Mogamulizumab is a monoclonal antibody that targets CCR4, a protein commonly found on malignant CTCL cells. In the MAVORIC trial, it outperformed vorinostat:

• Median progression-free survival: 7.7 months versus 3.1 months
• Confirmed overall response rate: 28% versus 5%

Its strength in the blood is especially relevant for SS. In MAVORIC, mogamulizumab produced a blood compartment response rate of 68%, with a median time to response of 1.1 months and a median response duration of 26 months.

ECP and mogamulizumab are often central to blood-involved disease management, sometimes used alongside other systemic agents depending on the individual case.

Pathway 3: Relapsed or Refractory CTCL: Exhausting Standard Options

This pathway applies to patients whose disease has progressed through skin-directed therapy, ECP, and/or one or more systemic agents. It is also where the newest FDA approvals and pipeline agents matter most.

Established and recently approved systemic options

• Brentuximab vedotin (Adcetris): An antibody-drug conjugate approved for CD30-expressing MF and primary cutaneous anaplastic large cell lymphoma after prior systemic therapy. In the ALCANZA trial, 56.3% of patients achieved a response lasting at least four months, compared with 12.5% with physician’s choice of therapy.
• Mogamulizumab: Used in relapsed MF and SS, with particular strength in blood involvement, as described above.
• Denileukin diftitox-cxdl (Lymphir): A fusion protein that targets the IL-2 receptor on malignant T-cells. It was FDA-approved in August 2024 for adults with relapsed or refractory stage I to III CTCL who have received at least one prior systemic therapy, with a 36.2% objective response rate in Phase 3 testing.
• HDAC inhibitors and bexarotene: Established agents used in many sequencing strategies.

Combination strategies

Researchers are testing combinations that attack CTCL through multiple pathways at once. Pairing HDAC inhibitors with PI3K inhibitors (such as tenalisib, duvelisib, or linperlisib) has produced 50% to 60% response rates in refractory cases, though these approaches remain investigational.

Lacutamab: a leading pipeline candidate

Lacutamab is an antibody targeting KIR3DL2, a protein frequently present on malignant cells in Sézary syndrome. It achieved a 43% overall response rate with a median response duration of 25.6 months in SS patients, and it received Breakthrough Therapy designation in February 2025.

In August 2026, Sobi and Innate Pharma formed a strategic partnership to advance lacutamab toward accelerated approval in Sézary syndrome, enabling initiation of the TELLOMAK-3 confirmatory Phase 3 trial. TELLOMAK-3 will compare lacutamab head-to-head against romidepsin in mogamulizumab-pretreated SS and against mogamulizumab in MF, with progression-free survival as the primary endpoint.

Signpost: When to Seek a Cutaneous Lymphoma Center of Excellence or Clinical Trial

Community dermatologists and oncologists manage many CTCL patients well. Certain situations, however, benefit from specialist input.

Clear referral triggers

• Progression despite two or more systemic therapies
• Diagnostic uncertainty, since early MF can resemble eczema or psoriasis
• Interest in investigational agents, such as lacutamab, HyBryte, or cellular therapies
• Need for ECP access that is not available locally

What specialist centers offer

• Clinical trial access, often unavailable outside academic centers
• Multidisciplinary staging expertise from dermatology, hematology-oncology, pathology, and radiation oncology working together
• Biomarker-driven therapy selection, using markers such as CD30 (brentuximab vedotin), CCR4 (mogamulizumab), and KIR3DL2 (lacutamab)

Questions to bring to a referral discussion

• Has biomarker testing for CD30, CCR4, or KIR3DL2 been performed?
• Is the current stage up to date, or is restaging needed?
• Are there clinical trials for which the patient may be eligible?
• Which therapies have been tried, and how long did each response last?

The pipeline makes these conversations increasingly worthwhile. According to 2026 pipeline assessments, more than 30 companies are developing over 35 CTCL therapies, and a 2026 peer-reviewed review cataloged 134 clinical trials spanning antibodies, epigenetic modifiers, signaling inhibitors, immunotherapies, and cellular therapies.

The Science of Why CAR-T Is Different in CTCL

CAR-T cell therapy has transformed treatment for many B-cell lymphomas. Patients with CTCL often ask why the same approach is not yet available to them. The answer lies in biology.

The fratricide problem

CAR-T therapy works by engineering a patient’s own T-cells to recognize and kill cancer cells carrying a specific surface marker. In CTCL, the cancer cells are themselves T-cells. They share many surface markers, such as CD4 and CD7, with the very T-cells engineered to destroy them.

When CAR-T cells are designed to target one of those shared markers, they may recognize each other as targets. This self-destruction is called fratricide, meaning “killing one’s siblings.” It can prevent CAR-T cells from expanding and persisting long enough to work.

Collateral damage to healthy immunity

Even when CAR-T cells survive, they may also attack the patient’s healthy T-cells carrying the same marker. Because T-cells are central to fighting infection, this can cause severe T-cell immunodeficiency.

Manufacturing risk

CAR-T products are made from the patient’s own blood. In blood-involved disease such as Sézary syndrome, malignant T-cells circulate alongside healthy ones. There is a risk of accidentally engineering malignant cells into the CAR-T product, which could then be reinfused.

Why B-cell lymphoma is different

In B-cell lymphoma, CAR-T cells target markers such as CD19 or CD20, which appear on B-cells but not on the T-cells used to build the therapy. The CAR-T cells do not attack themselves, and the immune system can tolerate loss of B-cells far better than loss of T-cells. This basic difference explains why cellular therapy for CTCL lags years behind.

Where research stands in 2026

Scientists have designed experimental CARs against CD4, CD5, CD7, CD30, CD37, CCR4, and the TRBC1/TRBC2 T-cell receptor chains, aiming to hit malignant cells selectively. Results remain early:

• A TRBC1-targeted CAR-T (AUTO4) in T-cell lymphoma produced only transient complete responses in 2 of 10 patients, with short CAR-T persistence.
• A separate CD4-targeted CAR-T study was stopped.
• Preclinical anti-CCR4 CAR-T cells (using the same target as mogamulizumab) induced long-term remission in mouse models, a promising but still experimental result.

Cellular therapy for CTCL holds long-term potential, but it is not yet a standard option outside clinical trials.

Comparing Treatment Decisions Side-by-Side: A Quick Reference

Pathway	Typical Patient	Primary Approach	Key Options
1. Skin-limited MF	Early-stage patches or plaques	Skin-directed therapy first	Topical steroids, mechlorethamine, retinoids, phototherapy, local radiation, TSEBT
2. Blood-involved SS / erythrodermic MF	Erythroderma with circulating malignant cells	Blood-targeted therapy from the outset	ECP, mogamulizumab, other systemic agents
3. Relapsed/refractory	Progression after prior therapies	Biomarker-driven systemic therapy plus trial options	Brentuximab vedotin, mogamulizumab, Lymphir, combinations, lacutamab and other trials

Consolidated escalation checklist

• [ ] No response after an adequate topical or phototherapy trial
• [ ] Increase in body surface area or lesion thickness
• [ ] New lymph node or blood involvement
• [ ] Reclassification to stage IIB or higher
• [ ] Progression despite two or more systemic therapies
• [ ] Diagnostic uncertainty or need for restaging
• [ ] Interest in investigational agents or need for ECP access

Treatment choice should always be individualized with the care team, accounting for biomarker status, response to prior therapy, symptoms such as itch, and overall health.

Conclusion: Navigating CTCL Therapy With Confidence

CTCL treatment is not one-size-fits-all. It is a staged, evolving pathway tied to where the disease currently sits. For many people with early MF, decades-proven skin-directed therapies provide long-term control. For those with blood involvement, ECP and mogamulizumab target the circulating disease directly. For relapsed or refractory disease, the toolkit now includes newly approved agents such as Lymphir and promising late-stage candidates such as lacutamab, while HyBryte may one day fill the gap in early-stage, first-line systemic care.

Cellular therapies like CAR-T hold long-term promise, but the biology of CTCL requires more scientific groundwork before they become standard care.

Knowing the “when to escalate” signposts helps patients and caregivers advocate for timely specialist referral or trial consideration. With FLASH2 results expected in the second half of 2026 and TELLOMAK-3 moving forward under the new Sobi and Innate Pharma partnership, 2026 is shaping up as a pivotal year for the field.

Next Steps: Talk to a Specialist About Your CTCL Treatment Plan

Patients and caregivers can use this guide as a discussion framework at the next appointment. Practical steps include:

• Review staging and response: Ask the dermatologist or hematologist-oncologist to confirm the current stage and how the disease has responded to each therapy.
• Ask about biomarker testing: Request information on CD30, CCR4, and KIR3DL2 status and how results could guide therapy selection.
• Consider specialist referral: If standard therapy is not achieving durable control, ask about referral to a cutaneous lymphoma center of excellence.
• Explore clinical trials: Ask the care team about trial eligibility for emerging agents such as lacutamab or HyBryte, and search public clinical trial registries with their help.
• Bring specific questions: Identify which pathway applies today and which signposts would signal a change.

Informed questions lead to better conversations, and better conversations lead to treatment plans that fit each patient’s disease and goals.